A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Top Cited Papers
Open Access
- 2 August 2016
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 87 (5), 539-547
- https://doi.org/10.1212/wnl.0000000000002923
Abstract
Biomarkers have become an essential component of Alzheimer disease (AD) research and because of the pervasiveness of AD pathology in the elderly, the same biomarkers are used in cognitive aging research. A number of current issues suggest that an unbiased descriptive classification scheme for these biomarkers would be useful. We propose the “A/T/N” system in which 7 major AD biomarkers are divided into 3 binary categories based on the nature of the pathophysiology that each measures. “A” refers to the value of a β-amyloid biomarker (amyloid PET or CSF Aβ42); “T,” the value of a tau biomarker (CSF phospho tau, or tau PET); and “N,” biomarkers of neurodegeneration or neuronal injury ([18F]-fluorodeoxyglucose–PET, structural MRI, or CSF total tau). Each biomarker category is rated as positive or negative. An individual score might appear as A+/T+/N−, or A+/T−/N−, etc. The A/T/N system includes the new modality tau PET. It is agnostic to the temporal ordering of mechanisms underlying AD pathogenesis. It includes all individuals in any population regardless of the mix of biomarker findings and therefore is suited to population studies of cognitive aging. It does not specify disease labels and thus is not a diagnostic classification system. It is a descriptive system for categorizing multidomain biomarker findings at the individual person level in a format that is easy to understand and use. Given the present lack of consensus among AD specialists on terminology across the clinically normal to dementia spectrum, a biomarker classification scheme will have broadest acceptance if it is independent from any one clinically defined diagnostic scheme.Keywords
This publication has 60 references indexed in Scilit:
- PET Imaging of Tau Deposition in the Aging Human BrainNeuron, 2016
- Tau positron emission tomographic imaging in aging and early Alzheimer diseaseAnnals of Neurology, 2015
- Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's DiseaseJournal of Neuroscience, 2015
- The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PETAlzheimer's & Dementia, 2014
- Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian DisordersArchives of Neurology, 2012
- Modifiable factors that alter the size of the hippocampus with ageingNature Reviews Neurology, 2012
- Introduction to the recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseAlzheimer's & Dementia, 2011
- Cerebrospinal Fluid tau/β-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older AdultsArchives of Neurology, 2007
- Simultaneous Measurement of β-Amyloid(1–42), Total Tau, and Phosphorylated Tau (Thr181) in Cerebrospinal Fluid by the xMAP TechnologyClinical Chemistry, 2005
- Cerebrospinal fluid Aβ42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsyMovement Disorders, 2002